Successful siRNA therapeutics requires the optimal integration of multiple components, including an efficient delivery system, a disease indication that is appropriate for siRNA-based therapy, and a potent and non-toxic siRNA against a robust therapeutic target. Although all currently available delivery systems have limitations, it is important to recognize that a careful selection of the disease indication, therapeutic target, and siRNA molecule could partially compensate for deficiencies associated with the delivery system and makes it possible to advance a therapeutic siRNA regimen with an imperfect delivery platform. In this study, we presented the development of siRNA therapeutics for hepatocellular carcinoma using an integrated approach, including the development of an efficient lipid nanoparticle delivery system, the identification of a robust therapeutic target that do not trigger liver toxicity upon target knockdown, and the selection of potent and non-immunogenic siRNA molecules against the target. The resulting siRNA-containing lipid nanoparticles produced significant anti-tumor efficacy in orthotopic hepatocellular carcinoma models, and thus, represent a promising starting point for the development of siRNA therapeutics for hepatocellular carcinoma.
Developing
Lipid Nanoparticle-based siRNA 
Introduction
Short interfering RNA (siRNA) represents a promising novel therapeutic modality for the treatment of cancer (1) . However, delivering siRNA to tumors using clinically acceptable delivery strategies remains a major technical hurdle (2, 3) . Over the last 10 years, various proof-of-concept successes of in vivo siRNA delivery to tumors have been reported using delivery vehicles such as liposomes, cationic polymers and other materials (4) (5) (6) (7) (8) (9) (10) . To select the most promising delivery platform for the development of siRNA therapeutics, we evaluated the majority of available delivery technologies for their abilities to deliver siRNA into tumors using the previously-described positive-readout tumor models (11) . From these analyses, lipid nanoparticles such as Stable Nucleic Acids
Lipid Nanoparticles (SNALP) emerged as the most promising platform for tumor delivery via systemic administration. SNALP is a lipid nanoparticle of ~100 nm in size and has a close to neutral surface charge (12) (13) (14) . It consists of cholesterol, DSPC, DLin-DMA and PEG-C-DMA. Among these components, the neutral lipids DSPC and cholesterol are commonly used in many liposome formulations for maintaining liposome structure whereas, PEG-C-DMA and D-Lin-DMA are unique components of SNALP that are critical for its in vivo delivery efficiency (15, 16) .
Although delivery is often the primary focus of most therapeutic siRNA programs, it is important to recognize that a successful siRNA drug requires an optimal integration of multiple components: an efficient delivery system, a potent non-toxic siRNA, a robust therapeutic target, and a carefully selected disease indication. Because all current delivery technologies have various limitations, a careful selection of the disease indication, disease target, and siRNA sequences will likely be required to compensate for deficiencies associated with current delivery technologies in order to maximize the chances of success.
Here we report the development of a siRNA-based approach for the treatment of hepatocellular carcinoma using an integrated approach, including the discovery of a siRNA delivery system that has equivalent tumor delivery efficiency but reduced adverse effect compared with SNALP, and the identification of therapeutic targets and siRNA molecules that allow selective targeting of liver tumors without triggering overt liver toxicity. The resulted siRNA-containing lipid nanoparticles produced robust anti-tumor efficacy in an orthotopic hepatocellular carcinoma model, and thus, represents a promising starting point for the development of siRNA therapies for HCC.
Materials and Methods
Reagents and cell lines. The positive readout reporter cell line, Tet-ODC-Luc, and the TetR siRNA used in the study were previously described (11) . HepG2 and HuH7 cells were obtained from ATCC more than 10 years ago. Aliquots of low passage cells from original purchasing were kept in liquid nitrogen and were revived and cultured at conditions suggested by the vendor. The revived cells were passaged in culture for less than 3 months before replaced with a newly revived batch for experiments. D-Lin-DMA, PEG-C-DMA, and various proprietary cationic lipids and PEG lipids were synthesized at Abbott (17) . The poly (I:C) was purchased from Sigma (St. Louis, MO). Human RAN antibody was obtained from Cell Signaling (Beverly, MA).
Lipid nanoparticle formulation. SNALP was prepared according to the literature-described procedure (7) . D-Lin-DMA and PEG-C-DMA were formulated with DSPC, Cholesterol, and siRNA using a 25:1 lipid/siRNA ratio and a 48/40/10/2 molar ratio of Cholesterol/D-Lin-DMA/DSPC/PEG-C-DMA. The resulted SNALP liposomes have similar characteristics to what was described in the literature (80 nm -100 nm in size, PDI <0.1, and a close to neutral zeta potential). Lipid nanoparticles containing inhouse lipids were prepared using a needle injection method that was described earlier (18) . Briefly, solutions of lipid mixtures were prepared in ethanol, injected into siRNA-containing citrate buffer through a 27-gauge needle. The resulted particle suspension was then diluted in phosphate buffered saline (PBS, pH 7.4) followed by 4 cycles of diafiltration against PBS, sterile filtered and stored at 4 o C.
0 B Tumor models, animal dosing, and bioluminescence imaging analysis. The animal studies were carried out in accordance with internal Institutional Animal Care and Use Committee (IACUC) guidelines at Abbott Laboratories. All animals were obtained from Charles River Laboratory. TetR-ODC-Luc, HepG2, or HuH7 cells were inoculated into the liver of 6 to 8 week-old Scid female mice to create various liver tumor models.
For in vivo knockdown evaluation in the positive-readout model, treatments were started 3~ 4 weeks after tumor inoculation for liver tumors. Mice bearing the TetR-ODC-Lucderived liver tumors were imaged on day 1, administrated with lipid nanoparticles on day 1 and day 2 (i.v., 2.5 mg siRNA/kg), and re-imaged on day 4 (48 hours after the last dose). In vivo bioluminescence imaging and analysis were conducted on the IVIS 200 system using the Living Image acquisition and analysis software (Caliper Life Science, Hopkinton, MA) as previously described (11) . Briefly, after intra-peritoneal injection of luciferin (Promege, Madison, WI) at 150 mg/kg, mice were anesthetized with isofluorane. Four minutes after the injection of luciferin, a series of time-lapse images were acquired at 2 minutes intervals in a total of 10 minutes. Regions of interest (ROI) were drawn around the tumors and signal intensity was quantified as the sum of photon counts per second within the ROI after the subtraction of background luminescence. The peak reading during the 10-minute imaging period was used for calculating the signal ratio before and after siRNA delivery. For anti-tumor efficacy studies, lipid nanoparticles were administrated 72 hours after cancer cell inoculation (i.v., 2.5 mg siRNA/kg, twice/week for three weeks). At the end of the efficacy trial, mice were humanly euthanized, and liver tumor nodules were surgically excised and weighted. For mice without visible tumors, the tumor weight was recorded as 0.
Separate liposomes from liposome /serum mixture. Sepharose column was prepared by adding Sepharose CL-4B (Sigma, St. Louis, MO) into 1.2ml plastic column (Bio-Rad, Hercules, CA) followed by centrifugation at 1000 rpm for 1 minute (Beckman ALGRA 6R). The Sepharose column was further washed once with 0.2ml PBS. Freshly prepared column was loaded with 100ul of liposome/fetal bovine serum mixture and centrifuged at 1000 rpm for 1 minute to collect the elute for MS analysis.
1 B In vivo tolerability assessment. Lipid nanoparticles containing different siRNAs were administrated to non-tumor-bearing Scid females via intravenous injection at 2.5 mg siRNA/kg, twice/week, for three weeks. At the end of the study, mice were humanely euthanized, serum ALT and AST levels were determined, and liver morphology was examined. Lipid nanoparticles that triggered significant increase of ALT or AST levels (> 4 fold over untreated control group), or >10% weight loss, or gross liver morphology changes (e.g. liver color change, liver fibrosis, etc.) were designated as intolerable.
containing different siRNAs were intravenously administrated at 2.5 mg siRNA/kg. Serum samples were harvested 2 hours after dosing, and the levels of a panel of cytokines and chemokines were determined using a multiplex assay (Luminex, Austin, TX).
Results
Impact of PEG shields on in vitro and in vivo activities of lipid nanoparticles.
The PEG lipid engrafts on lipid nanoparticles to form a PEG shield that tends to limit particle clearance by the reticular endothelial system, and therefore, is an essential component for modulating the PK properties that are critical for in vivo delivery. To better understand the impact of PEG shielding on in vitro and in vivo activities of lipid nanoparticles, we created SNALP-like lipid nanoparticles that contain PEG molecules with C14 (PEG-DMPE), C16 (PEG-DPPE), and C18 (PEG-DSPE) lipid anchors. These lipid nanoparticles encapsulate a siRNA targeting tet repressor (siTetR), thus allowing convenient in vitro and in vivo testing using the previously described TetR-ODC-Luc cells, a positive-readout cell line where successful delivery of siTetR into cells leads to an increase of luciferase activity (11) . Incubating lipid nanoparticles containing PEG-DMPE with TetR-ODC-Luc resulted in a robust increase of luciferase reporter activity, indicating efficient delivery of the tetR siRNA into these cells. Lipid nanoparticles containing PEG-DPPE and PEG-DSPE only exhibited moderate and marginal activities, suggesting that these particles deliver siRNAs into cells less efficiently ( Figure 1A) . incubating the lipid nanoparticles with serum, recovering intact particles overtime using Sepharose spin columns, and quantifying remaining PEG-lipid on the particle. As shown in Figure 1C , PEG-DMPE quickly dissociated from lipid nanoparticle; whereas, no apparent deshielding was observed in the same time frame for PEG-DPPE and PEG-DSPE. Consistent with their rapid deshielding, the PEG-DMPE-containing particles quickly disappeared from systemic circulation after intravenous administration (a >50% reduction of circulating particles within 5 minutes and nearly 90% reduction of circulating particles at 60 minutes). In contrast, the PEG-DPPE-and PEG-DSPEcontaining particles stayed in circulation for a much longer period of time (>70% particles remained in circulation at 5 minutes and nearly 40% particles remained in the circulation at 60 minutes) ( Figure 1D ). Collectively, these results indicate that PEG shielding can have a dramatic effect on the in vitro and in vivo activities of lipid nanoparticles, and optimal tumor delivery will require a properly anchored PEG shield to achieve the right balance between cellular activities and in vivo PK/tissue distribution properties.
Development of novel lipid nanoparticles via a two-step screen.
In view of the impact of PEG shielding on in vitro and in vivo activities, we designed a two-step approach for the development of novel lipid nanoparticle delivery systems. In the first step, novel cationic lipids were formulated with DSPC, Cholesterol, and PEG-cholesterol to form "rapid-deshielding" lipid nanoparticles for in vitro determination of transfection activity. Due to its short cholesterol anchor, PEG-cholesterol is expected to shed quickly from the particle under tissue culture conditions, yielding a "naked" particle for active transfection. Therefore, the PEG-cholesterol-shielded lipid nanoparticles allow us to examine the "intrinsic" ability of the cationic lipid to mediate siRNA transfection without interference from the PEG shield. An example of the in vitro screen is shown in Figure   2A , where different lipids were formulated into PEG-Cholesterol-shielded nanoparticles containing the tetR siRNA and tested for transfection activities in the TetR-ODC-Luc cells. Nanoparticles containing cationic lipid A-066 induced a robust increase of luciferase activity, suggesting that A-066 may be a promising component for developing novel siRNA delivery systems.
In the second step, cationic lipids that show promise from in vitro screen were used to form nanoparticles containing various commercial or proprietary PEG lipids.
These nanoparticles were then screened in vivo using the positive-readout tumor models to identify the appropriate PEG shields for a particular cationic lipid. An example of the in vivo screen is shown in Figure 2B . A-066 was formulated with DSPC/Cholesterol, different PEG lipids and the TetR siRNA. The resulting nanoparticles were tested for siRNA delivery using the TetR-ODC-Luc cell-derived orthotopic liver tumor model. A number of nanoparticles induced a significant increase of luminescent signal, indicating successful siRNA delivery into tumors. Among these, the A-066-derived nanoparticles containing PEG shields formed by TMH400, PEG-DPG, or PEG-DMG appeared to exhibit the best in vivo activity. These stepwise in vitro and in vivo screens led to the identification of a number of promising cationic lipids and PEG lipids for siRNA delivery (17) .
Once a promising pair of cationic lipid and PEG lipid was identified, formulation optimization was carried out by varying the percentage of cationic lipid or PEG-lipid, using different neutral lipids, or altering formulation conditions such as processing temperature, buffer pH, etc. These formulation variants were then tested for various physiochemical properties and for in vivo delivery efficiency in the TetR-ODC-Luc liver tumor models to select the best candidate (18) . From these studies, nanoparticles containing A-066/TMH400/DSPC/Cholesterol at a 40/2/10/48 molar ratio and a total lipid/siRNA ratio of 25:1 emerged as one of the most active in vivo formulations that also maintain desirable properties such as excellent formulation reproducibility, uniform 100 nm particle size with PDI<0.1, a close to neutral surface charge, and more than 6 months stability in PBS etc (data not shown).
A-066/TMH400 exhibits similar tumor delivery efficiency as SNALP but triggers less adverse effects. Because SNALP is perceived as one of the best siRNA delivery system in the field, we compared A-066/TMH400 nanoparticles with SNALP for their abilities to deliver siRNA into tumors and their potential adverse impact on the liver, a major target tissue for lipid nanoparticles. A-066/TMH400 containing the tetR siRNA (A-066/TMH400-siTetR) produced a similar or better degree of target knockdown compared to SNALP-siTetR in the positive readout model ( Figure 3A Figure 3C with efficacy in our earlier report (19) .
Interestingly, although A-066/TMH400 and SNALP delivered siRNA into tumors with largely equivalent efficiency, their impact on the liver appeared to be different. In a 3-day liver toxicity study, intravenous administration of SNALP containing a control siRNA (SNALP-NTC) for two consecutive days induced high levels of the liver enzymes ALT and AST at doses of 5 mg/kg or higher ( Figure 4A ) and caused a pronounced discoloring of the liver (data not shown), indicating that SNALP caused liver damage at these doses. In contrast, neither significant induction of liver enzymes nor liver color change was observed for A-066/TMH400-NTC at all doses, suggesting that the A- Selection of therapeutic targets and siRNA molecules. Although lipid nanoparticles are by far the most efficient siRNA delivery system in our hands, they are far from ideal regarding their tumor delivery efficiency. For example, we have shown previously that SNALP-like lipid nanoparticles only deliver siRNAs to areas adjacent to tumor blood vessel, and consequently, high degrees of tumor vascularization is often required for efficient siRNA delivery (19) . In fact, when SNALP was used for siRNA delivery, even in the highly vascularized HepG2 liver tumors, significant target knockdown was only observed using a hyper-potent Ran siRNA (EC50 = 0.09 nM) but not a fairly potent Bcl-XL siRNA (IC50 = 0.9 nM). In contrast, robust target knockdown in the liver was observed using the same Bcl-XL siRNA, suggesting that SNALP delivers siRNA more efficiently into liver than tumor (data not shown). Taken all together, we believe that with the limitations of current delivery systems, significant therapeutic benefit will most likely be obtained in highly vascularized tumors (e.g. HCCs) using an exceptionally potent siRNA against a very robust therapeutic target. In addition, the therapeutic siRNA should be highly selective in killing tumor cells relative to liver cells in order to avoid the toxicity associated with target inhibition in the liver.
The in vivo efficacy/toxicity profile of a therapeutic siRNA ultimately reflects the combination of three inter-connected factors that include: 1) potency of the best available siRNA, 2) the biological robustness of the underlying targets for cancer cells, and 3) the selectivity for cancer over liver cells. Thus, we employed an empirical approach that takes these three factors into consideration for the selection of therapeutic targets and 
Discussion
The lack of clinically relevant methods for delivering siRNA into tumors remains a major technical hurdle for the development of therapeutic siRNA for oncology indications. In order to deliver siRNA into tumors via the systemic route, the delivery system need to satisfy the following requirements: 1) protects siRNA from nuclease degradation in circulation, 2) exhibits a proper PK and tissue distribution profile to deliver siRNA to disease-relevant organs/tissues, and 3) facilitates efficient uptake of siRNA into target cells and releases siRNA into cytoplasma to knockdown the target.
Technical solutions for each individual requirement largely exist owning to several decades of research on gene delivery technologies. However, to integrate all solutions into one delivery system is highly challenging. In particular, properties that are beneficial for cellular activities such as highly positive surface charge and high fusogenicity are often detrimental for PK properties that are critical for in vivo performance. Conversely, attempts to stabilize/shield nanoparticles in the bloodstream to improve the PK and tissue distribution profile often reduce the ability of nanoparticles to enter cells or escape from endosome, leading to a reduction or loss of cellular activity. Some of these issues were exemplified by the differential in vitro and in vivo activities of lipid nanoparticles with various PEG shields. As shown in Figure 1 , nanoparticles with the optimal in vitro activity did not exhibit any meaningful activity in vivo likely due to their poor PK properties; whereas particles without in vitro activity turn out to be highly active in vivo.
It has been shown that the strength of the interaction between the anchor moiety on PEG and the membrane lipids determines the rate and extent of PEG-Lipid extraction/exchanging to plasma proteins. PEG-lipids with longer acyl chain confer stronger interaction with membrane lipids thus less likely to be extracted/exchanged, and consequently, PEGs with longer lipid anchor are often associated with a slower rate of deshielding (16, (20) (21) (22) . Our results suggest that PEG-DMPE may be shed rapidly to expose the "naked" lipid particle consisting of fusogenic lipid D-Lin-DMA, which allows it to fuse with the cell membrane to achieve efficient siRNA transfection in vitro. emerged as a promising target for the development of siRNA-based therapy for HCC.
CDCA1 is part of the kinetochore-associated NDC80 complex, which is essential for chromosome segregation and spindle checkpoint function. siRNA-mediated targeting of CDCA1 potentially represents a new way of discrupting the mitotic machinery for cancer therapy. The emphasis on using an extremely potent siRNA for the development of siRNA therapy is often overlooked. It is important to recognize that improving the best currently available delivery system to achieve a 10-fold better delivery efficiency will be extremely difficult. However, obtaining a 10-to 100-fold more potent siRNA for a given target or finding a biologically equivalent target for which there is a 10-or 100-fold more potent siRNA available are technically feasible and may achieve the same or better therapeutic effect than a 10-fold improvement on the delivery system. Toward this end, the efficacy/toxicity profile of the A-066/TMH400-CDCA1_1.2 formulation can be greatly improved if a more potent CDCA1 siRNA can be obtained via a thorough siRNA sequence search or by incorporating chemical modifications to boost siRNA potency. It is noteworthy that the potency of the best siRNA differs significantly across targets (ranging from 0.001 nM to > 5 nM), which may result from the intrinsic differences on target sequence and/or the secondary structure of target mRNA. Therefore, it is conceivable that carrying out an extensive siRNA sequence search on CDCA1 partners within the NDC80 complex may reveal siRNAs that trigger the same biological response as the CDCA1_1.2 siRNA but with significantly better potency than the current CDCA1
siRNA, which could be a promising alternative towards obtaining better therapeutic formulations than the current A-066/TMH400_CDCA1_1.2 lipid nanoprticles. To determine the IC50 of siRNA, each siRNA was transfected into relevant cancer cell lines using lipofectatmine 2000. mRNA level of the target gene was then determined using the branched DNA assay (bDNA). For tolerability determination, each siRNA was formulated into the lipid nanoparticle formulation and administrated via i.v. into nonetumor-bearing mice at 2 mg siRNA/kg, twice/week for three weeks. Tolerability was monitored via body weight change, increase of ALT and AST, as well as gross liver morphology and color changes at the end of the dosing period.
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